--To the press -
FRONTEO announces new version of drug discovery support AI "Cascade Eye"
Added personalization function in drug discovery target analysis
Masahiro Morimoto, President and CEO
東京 都 港区 港 南 2-12-23
(Code number: 2158 TSE Mothers)
FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) has announced the drug discovery support AI "Cascade Eye Ver. 1.2".
Cascade Eye uses FRONTEO's natural language analysis AI engine "Concept Encoder (trademark: concept encoder, reading: concept encoder)" to analyze paper information and medical information, and pathways molecules and genes related to the disease to be analyzed. It is an AI system that displays in the form of a map (route map showing relevance).It is highly evaluated that it not only promotes the selection of new drug discovery targets and the efficiency of drug repositioning (diversification of existing drugs to other diseases) research, but also enables drug discovery analysis that is not affected by the bias of researchers. Since its release in 2020, it has been introduced by multiple pharmaceutical companies and academia.
In Cascade Eye Ver. 1.1, if you want to extract only the part directly related to a specific molecule or gene contained in the pathway map displayed by AI, processing in a separate process was required, but this version By uploading, you can now enlarge the route map only around a specific molecule / gene by simply selecting the molecule / gene in the map and double-clicking it.Also, in the past, partial extraction of the pathway map could only be performed from the start point (causative molecule / gene) of the pathway map, but in Ver. 1.2, the end point and intermediate part (responsive molecule / gene, etc.) of the pathway map can be extracted. ), And the target that can be analyzed has expanded dramatically.
Double-click the molecule / gene you want to check in detail from the entire pathway map.
Extract only the pathway map around the molecule / gene
In addition, not only published papers and databases, but also data held by companies and research institutes that have introduced this system will be added to the sources referenced by AI, and each company and research institution will research with its own database. It is now possible.
FRONTEO will promote DX (digital transformation) and efficiency improvement of drug discovery research through AI research and development, and will contribute to the realization of a "disease-free world that cannot be cured".
■ About Cascade Eye
"Cascade Eye" uses FRONTEO's natural language analysis AI engine "Concept Encoder" to analyze papers and medical information, and pathway maps (path maps showing relevance) of molecules and genes related to the disease to be analyzed. It is an AI system that displays in the form of).It visualizes the relationships between molecules and genes, and supports a significant improvement in the efficiency of the target search process in drug discovery research. Since AI comprehensively searches a huge amount of information that cannot be read by humans, it is possible to discover new drug discovery targets and diversion of existing drugs to other diseases without being influenced by researcher bias. It enables drug discovery approaches that were difficult with conventional methods, such as identification of unknown biomarkers.
■ About Concept Encoder
"Concept Encoder" is a natural language analysis AI (artificial intelligence) developed by FRONTEO specially in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. Concept Encoder can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals, and various test values accumulated in the life science field.Patent registration number: Patent No. 6346367
■ About FRONTEO URL:https://www.fronteo.com/
FRONTEO uses the in-house developed AI engine "KIBIT" and "concept encoder" specializing in natural language processing to extract meaningful and important information from a huge amount of text data to support corporate business. A data analysis company. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support international litigation of companies. Has been deployed.Based on the AI technology cultivated in the legal tech business, we expanded the business field to the life science field, business intelligence field, and economic security from 8, and by using AI to "turn text data into knowledge" , Drug discovery support, dementia diagnosis support, financial / human resources / sales support, etc., contributing to solving various corporate issues. Listed on TSE Mothers on June 2014, 2007. January 6 Obtained a first-class medical device manufacturing and sales license (permit number: 26B2021X1).The capital is 13 thousand yen (as of March 1, 10350).
* FRONTEO, KIBIT, conceptencoder, and Cascade Eye are registered trademarks of FRONTEO in Japan.